Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes

December 04, 2025 at 03:00 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

The companies have entered into a new collaboration where LabGenius Therapeutics will apply its ML-driven antibody discovery platform (EVA™) to optimise potential therapeutic NANOBODY® proteins for multiple new targets

LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, today announced a second collaboration with Sanofi. This collaboration combines LabGenius’ AI/ML-driven antibody design capabilities with Sanofi’s expertise in the development of therapeutic NANOBODY® molecules to co-optimise proteins for therapeutically valuable properties. Following the success of their first collaboration, LabGenius will apply the EVA™ platform to optimise NANOBODY® molecules for multiple new targets in the area of inflammation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204759388/en/

“We are truly excited about this new collaboration with Sanofi,” said LabGenius’ CSO, Dr. Angus Sinclair. “This partnership serves as strong validation of our platform’s unique ability to tackle complex antibody co-optimisation challenges across a wide range of therapeutic targets, ultimately driving better outcomes for patients.”

About LabGenius Therapeutics

LabGenius Therapeutics is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVA™, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. LabGenius Therapeutics operates a hybrid business model that includes partnering with biotech and pharmaceutical companies in parallel with pursuing a wholly-owned therapeutic pipeline. For more information, please visit www.labgeniustx.com, or connect on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251204759388/en/

This collaboration combines LabGenius’ AI/ML-driven antibody design capabilities with Sanofi’s expertise in the development of therapeutic NANOBODY® molecules to co-optimise proteins for therapeutically valuable properties

Contacts

Media: press@labgeni.us

Corporate / business development: partnerships@labgeni.us

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol

Price

Change (%)

AMZN

237.50

-8.50 (-3.46%)

AAPL

295.95

-3.29 (-1.10%)

AMD

512.48

+512.43 (1010708.68%)

BAC

56.53

+56.52 (1009364.29%)

GOOG

362.10

-9.00 (-2.43%)